RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring’s Rebyota® and Clenpiq®
Rhea-AI Summary
RedHill Biopharma (Nasdaq: RDHL) announced a transformational deal with Ferring Pharmaceuticals, acquiring exclusive global commercialization rights to Rebyota and exclusive U.S. rights to Clenpiq. According to RedHill, the products generated approximately $37.5 million in U.S. net sales in 2025 ($16.9 million Rebyota, $20.6 million Clenpiq).
Under the agreement, RedHill pays Ferring a $12 million upfront fee, fully funded from the previously announced $18 million Talicia divestiture, plus potential milestones and tiered royalties. Ferring retains Rebyota manufacturing and will supply product for the agreement term. Rebyota, FDA-approved in 2022 and Health Canada-approved in 2025, has Breakthrough Therapy and Orphan Drug designations with protections that could run to 2036. Clenpiq is a ready-to-drink, low‑volume bowel preparation with 2025 U.S. net sales of $20.6 million and broad payer coverage. The transaction is positioned by RedHill as completing a major strategic repositioning of its commercial gastrointestinal business.
Positive
- $12 million upfront secures exclusive global Rebyota and U.S. Clenpiq rights
- Acquired products generated about $37.5 million U.S. net sales in 2025
- Upfront payment fully funded from prior $18 million Talicia divestiture
- Rebyota benefits from regulatory and patent protections potentially through 2036
Negative
- Agreement includes ongoing tiered royalties and potential milestone payments to Ferring
Market reaction after GI commercialization rights acquisition: RDHL -3.32%
Following this news, RDHL has declined 3.32%, reflecting a moderate negative market reaction. Our momentum scanner has triggered 21 alerts so far, indicating elevated trading interest and price volatility. The stock is currently trading at $0.87.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 31 | Talicia divestiture | Positive | +36.2% | Divestiture generated upfront cash and potential milestones to fund commercial expansion. |
| Jul 28 | Ebola development update | Positive | +4.3% | Opaganib development update accompanied by Ebola outbreak and clinical data disclosures. |
| Jun 22 | Private placement closing | Negative | +10.2% | Private placement provided liquidity but introduced potential warrant-related dilution. |
| Jun 18 | Private placement announcement | Negative | +3.7% | Proposed equity and warrant financing was intended to support acquisition and working capital. |
| Jun 09 | FDA designation | Positive | -21.6% | FDA granted rare pediatric disease designation to opaganib for neuroblastoma. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
RDHL aligned with positive strategic and operational news in two recent events but diverged from positive news in three others.
Key Terms
fecal microbiota transplant medical
breakthrough therapy regulatory
orphan drug designation regulatory
tiered royalties financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Together with the previously announced Talicia strategic divestiture, the acquisition from Ferring of commercialization rights to two larger, proprietary, established gastrointestinal (GI) FDA-approved drugs that together generated approximately
The divestiture of Talicia and the acquisition of the new GI products from Ferring create a catalyst for commercial growth through a materially larger GI business under RedHill’s control, with a significantly stronger liquidity position and provides additional growth and expansion opportunities
Under the terms of the agreement, RedHill obtained the exclusive commercialization rights for an upfront payment to Ferring of
The
Rebyota is a proprietary, first and only single-dose FDA-approved Fecal Microbiota Transplant (FMT for prevention of recurrent C. diff infection (rCDI). FDA-approved in 2022 and Health Canada-approved in 2025, Rebyota, was granted a Breakthrough Therapy and received Orphan Drug designations and generated approximately
Proprietary Clenpiq, a ready-to-use (no mixing required) low-volume bowel preparation on the U.S. market, generated
RALEIGH, N.C., Sept. 01, 2026 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced the transformational acquisition of exclusive global and U.S. commercialization rights to Rebyota and Clenpiq, from Ferring Pharmaceuticals (“Ferring”), as part of Ferring’s ongoing strategic refocusing.
Dror Ben-Asher, RedHill’s Chief Executive Officer, said: “We have executed a clear strategic sequence. We have monetized Talicia for
Mr. Ben-Asher added: “We thank Ferring for a smooth process to date and look forward to a successful collaboration.”
Under the terms of the agreement, RedHill obtained an exclusive global commercialization license of Rebyota and an exclusive U.S. commercialization license of Clenpiq, for an upfront payment to Ferring of
“Rebyota is a first-in-class microbiota-based therapy for prevention of recurrent Clostridioides difficile (C. diff) infection (rCDI) in individuals 18 years of age and older following antibiotic treatment for rCDI. FDA-approved in 2022, it generated approximately
C. diff (CDI) infection is a distressing and life-threatening condition – in developed countries it is the most common cause of healthcare-associated (HA) diarrhea. An estimated 3.6 million cases of CDI occur globally each year, including approximately half a million cases in the U.S. 30,000 Americans die every year due to CDI, with a global mortality rate of 1-in-10, rising to almost 1-in-3 in high-risk settings1. In the U.S., up to approximately 165,000 CDI cases result in one or more recurrences, indicating the need for use of prevention strategies.
Rebyota’s one-time administration, which requires no fasting, bowel prep or extended treatment timeframe, has demonstrated more than a
Rebyota, which was granted, Breakthrough Therapy and Orphan Drug designations - with exclusivities and other patent protections that could run to 2036, provides multiple growth opportunities, including recent approval in Canada. The existing approvals also provide the potential for additional approvals in other territories.
Colonoscopy is the cornerstone of GI practice, with more than 15 million colonoscopies performed in the U.S. annually. This number is rising, with follow-up needed after noninvasive screening tests that yield a positive result, an aging population, and guidelines that recommend testing at age 45 instead of age 50, contributing to an increased need for colonoscopy. Bowel preparation is not a pleasant process and is often poorly performed.
Clenpiq is a ready-to-drink low-volume bowel prep. Clenpiq is readily available to patients and has broad commercial and government payer coverage: More than 108 million lives (
RedHill was advised by Morningstar Law Group and Greenberg Traurig LLP on this transaction.
About RedHill Biopharma
RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on U.S. development and commercialization of drugs for gastrointestinal diseases, infectious diseases and oncology. RedHill promotes the FDA-approved gastrointestinal therapies Rebyota, for the prevention of recurrent C. diff infection (rCDI), and the bowel preparation treatment, Clenpiq. RedHill's key clinical late-stage development programs include: (i) opaganib (ABC294640), a first-in-class, orally administered sphingosine kinase-2 (SPHK2) selective inhibitor with anti-inflammatory, antiviral, metabolic and anticancer activity, targeting multiple indications with a track record of U.S. government and academic collaborations intended for medical countermeasure development including for EVD, radiation exposure indications such as GI-Acute Radiation Syndrome (GI-ARS), a Phase 2/3 program for hospitalized COVID-19, and an ongoing Phase 2 study in prostate cancer in combination with darolutamide; (ii) RHB-102 (Bekinda), with a planned Phase 2 proof-of-concept study for GLP-1/GIP receptor agonist-associated GI intolerance, positive results from a U.S. Phase 3 study for acute gastroenteritis and gastritis, positive results from a U.S. Phase 2 study for IBS-D and potential UK submission for chemotherapy and radiotherapy induced nausea and vomiting. RHB-102 is partnered with Hyloris Pharmaceuticals (EBR: HYL) for worldwide development and commercialization outside North America; (iii) RHB-204, a next-generation optimized formulation of RHB-104, with a planned Phase 2 study for Crohn's disease (based on RHB-104's positive Phase 3 Crohn's disease study results); and (iv) RHB-107 (upamostat), an oral broad-acting, host-directed, serine protease inhibitor with potential for pandemic preparedness, including COVID-19 and also targeting multiple cancer and inflammatory gastrointestinal diseases.
More information about the Company is available at www.redhillbio.com / X.com/RedHillBio.
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and may discuss investment opportunities, stock analysis, financial performance, investor relations, and market trends. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words, and include, among others, statements regarding the divestment of Talicia and the potential use of the proceeds of such sale; the expected benefits of the acquisition of commercialization rights to Rebyota and Clenpiq, the anticipated commercial growth and cash contribution from these products, expectations regarding market share growth, anticipated payer coverage, the Company’s strategic repositioning and path to operational profitability, potential use of milestone and royalty payments, and the Company’s ability to successfully commercialize Rebyota and Clenpiq. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements
[i] Akorful RAA, Odoom A, Awere-Duodu A, Donkor ES. The Global Burden of Clostridioides difficile Infections, 2016-2024: A Systematic Review and Meta-Analysis. Infect Dis Rep. 2025 Apr 14;17(2):31. doi: 10.3390/idr17020031. PMID: 40277958; PMCID: PMC12026862.
[ii] Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, Farley MM, Holzbauer SM, Meek JI, Phipps EC, Wilson LE, Winston LG, Cohen JA, Limbago BM, Fridkin SK, Gerding DN, McDonald LC. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015 Feb 26;372(9):825-34. doi: 10.1056/NEJMoa1408913. PMID: 25714160; PMCID: PMC10966662.
[iii] Feuerstadt P, Theriault N, Tillotson G. The burden of CDI in the United States: a multifactorial challenge. BMC Infect Dis. 2023 Mar 7;23(1):132. doi: 10.1186/s12879-023-08096-0. PMID: 36882700; PMCID: PMC9990004.
[iv] Khanna S, Assi M, Lee C, et al. Efficacy and safety of RBX2660 in PUNCH CD3, a phase III, randomized, double-blind, placebo-controlled trial with a Bayesian primary analysis for the prevention of recurrent Clostridioides difficile infection. Drugs. 2022;82(15):1527-1538. doi:10.1007/s40265-022-01797-x.
[v] Data on file. Ferring Pharmaceuticals
[vi] MarketScan Commercial Claims and Encounters and Medicare Supplemental database
Contact
Chief Corporate and BD Officer
Adi Frish
RedHill Biopharma
adi@redhillbio.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/b4f73c57-9f49-4c60-8d50-4abafd908297
